Listen

Press releases

Receive e-mail alerts

Interne link L’Agence européenne des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10
juli 29, 2019 om 04:37 PM UTC
Interne link European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10
juli 29, 2019 om 11:00 AM UTC
Interne link ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July
juli 02, 2019 om 11:00 AM UTC
Interne link ProQR to Present at the JMP Securities Life Sciences Conference
juni 03, 2019 om 11:00 AM UTC
Interne link ProQR to Present at the RBC Capital Markets Healthcare Conference
mei 15, 2019 om 11:00 AM UTC
Interne link ProQR Announces Financial Results for the First Quarter of 2019
mei 08, 2019 om 11:00 AM UTC
Interne link ProQR to Present at Three Scientific Conferences in April
april 22, 2019 om 11:00 AM UTC
Interne link ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board
april 18, 2019 om 11:00 AM UTC
Interne link ProQR Announces Annual Meeting of Shareholders
april 18, 2019 om 11:00 AM UTC
Interne link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
april 15, 2019 om 11:00 AM UTC
Interne link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference
april 01, 2019 om 11:00 AM UTC
Interne link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
maart 26, 2019 om 08:01 PM UTC
Interne link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2
maart 11, 2019 om 04:45 PM UTC
Interne link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
maart 11, 2019 om 12:00 PM UTC
Interne link ProQR to Present at Cowen Health Care Conference
maart 05, 2019 om 12:00 PM UTC
Interne link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
februari 27, 2019 om 12:00 PM UTC
Interne link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
januari 29, 2019 om 01:30 PM UTC
Interne link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
januari 07, 2019 om 12:00 PM UTC
Interne link ProQR to Host R&D Day in New York on January 29
januari 03, 2019 om 12:00 PM UTC
Interne link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
januari 02, 2019 om 12:00 PM UTC
Interne link ProQR Therapeutics Added to NASDAQ Biotechnology Index
december 24, 2018 om 12:00 PM UTC
Interne link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10
december 18, 2018 om 03:27 PM UTC
Interne link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10
december 17, 2018 om 04:52 PM UTC
Interne link ProQR Announces Strategic Changes to the Management Team and Key New Hires
december 13, 2018 om 12:00 PM UTC
Interne link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10
december 10, 2018 om 12:00 PM UTC

Press releases

Interne link L’Agence européenne des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10

Interne link European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10

Interne link ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July

Interne link ProQR to Present at the JMP Securities Life Sciences Conference

Interne link ProQR to Present at the RBC Capital Markets Healthcare Conference

Interne link ProQR Announces Financial Results for the First Quarter of 2019

Interne link ProQR to Present at Three Scientific Conferences in April

Interne link ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board

Interne link ProQR Announces Annual Meeting of Shareholders

Interne link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

Interne link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference

Interne link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership

Interne link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2

Interne link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

Interne link ProQR to Present at Cowen Health Care Conference

Interne link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

Interne link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day

Interne link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10

Interne link ProQR to Host R&D Day in New York on January 29

Interne link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

Interne link ProQR Therapeutics Added to NASDAQ Biotechnology Index

Interne link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10

Interne link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10

Interne link ProQR Announces Strategic Changes to the Management Team and Key New Hires

Interne link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10